Tetyana Roytman
Family · Brooklyn, NYNPI 1982249868
Payments from drug & device makers
Across 276 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$603
- SK Life Science, Inc.$398
- Arbor Pharmaceuticals, Inc.$365
- Biogen$276
- Harmony Biosciences LLC$274
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,590100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,458 |
| UCB, Inc. | 39 | $603 |
| SK Life Science, Inc. | 4 | $398 |
| Arbor Pharmaceuticals, Inc. | 15 | $365 |
| Biogen | 13 | $276 |
| Harmony Biosciences LLC | 17 | $274 |
| Scilex Pharmaceuticals Inc. | 13 | $271 |
| Neurocrine Biosciences, Inc. | 12 | $249 |
| Azurity Pharmaceuticals, Inc. | 15 | $244 |
| Lilly USA, LLC | 10 | $204 |
| Otsuka America Pharmaceutical, Inc. | 10 | $150 |
| Amneal Pharmaceuticals LLC | 7 | $144 |
| Eisai Inc. | 5 | $117 |
| Lundbeck LLC | 6 | $106 |
| Neurelis, Inc. | 6 | $94 |
| Avanir Pharmaceuticals, Inc. | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Sanofi | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Amgen | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Merck | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,590 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 27 | $47,259 |
| UbrelvyUbrogepant | 24 | $30,406 |
| Diclofenac Sodium | 43 | $23,287 |
| Dihydroergotamine Mesylate | 24 | $22,726 |
| TrintellixVortioxetine Hydrobromide | 33 | $21,874 |
| Emgality PenGalcanezumab-Gnlm | 19 | $13,222 |
| NeuproRotigotine | 12 | $12,779 |
| GraliseGabapentin | 23 | $12,163 |
| HorizantGabapentin Enacarbil | 14 | $9,285 |
| ZtlidoLidocaine | 20 | $7,032 |
| Memantine Hcl ErMemantine Hcl | 77 | $6,945 |
| Trokendi XrTopiramate | 11 | $5,074 |
| Diclofenac Epolamine | 17 | $4,895 |
| Rivastigmine | 23 | $3,074 |
| Duloxetine Hcl | 101 | $1,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $22 | $47,25927 claims |
| AbbVieUbrelvy | $1,458 | $30,40624 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $78 | $21,87433 claims |
| UCB, Inc.Neupro | $603 | $12,77912 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $365 | $9,28514 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $271 | $7,03220 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $15 | $5,07411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.